YLIU-4-105-1

YLIU-4-105-1 is a potent and selective type II JAK2 inhibitor. It demonstrates robust in vivo efficacy by dose-dependently reducing splenomegaly and reticulocytosis, and it directly suppresses JAK2 signaling via inhibition of pSTAT5. This compound is a valuable research tool for investigating JAK2-driven pathologies such as myeloproliferative neoplasms in both cellular and animal models.